REQUEST A DEMO
Total
USD $0.00
Search more companies

Aventis Pharma Manufacturing Pte Ltd (Singapore)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Aventis Pharma Manufacturing Pte Ltd Profile Updated: March 29, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Aventis Pharma Manufacturing Pte. Ltd. is engaged in manufacturing and supply of pharmaceutical ingredients. The company offers Nedocromil Sodium, Sodium Cromoglicate and Enoxaparin Sodium. Aventis Pharma Manufacturing Pte. Ltd. operates as a subsidiary of Sanofi. The company was founded in 1970 and is based in Singapore.

Headquarters
61 Gul Circle, Singapore
Singapore; Singapore; Postal Code: 629585

Contact Details: Purchase the Aventis Pharma Manufacturing Pte Ltd report to view the information.

Basic Information
Total Employees:
Purchase the Aventis Pharma Manufacturing Pte Ltd report to view the information.
Outstanding Shares:
Purchase the Aventis Pharma Manufacturing Pte Ltd report to view the information.
Financial Auditors:
Purchase the Aventis Pharma Manufacturing Pte Ltd report to view the information.
Incorporation Date:
March 31, 1970
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Company Secretary
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Aventis Pharma Manufacturing Pte Ltd report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency SGD. Absolute financial data is included in the purchased report.
Net sales revenue
-15.34%
Total operating revenue
-15.34%
Net Profit (Loss) for the Period
-15.49%
Total assets
3.99%
Total equity
17.84%
Net Profit Margin
-0.01%
Return on Equity (ROE)
-5.97%

Related EMIS Industry Reports

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?